Heat Shock Protein 90 (Hsp90)-Inhibitor-Luminespib-Loaded-Protein-Based Nanoformulation for Cancer Therapy
Open Access
Abstract
Drugs targeting heat shock protein 90 (Hsp90) have been extensively explored for their anticancer potential in advanced clinical trials. Nanoformulations have been an important drug delivery platform for the anticancer molecules like Hsp90 inhibitors. It has been reported that bovine serum albumin (BSA) nanoparticles (NPs) serve as carriers for anticancer drugs, which have been extensively explored for their therapeutic efficacy against cancers. Luminespib (also known as NVP-AUY922) is a new generation Hsp90 inhibitor that was introduced recently. It is one of the most studied Hsp90 inhibitors for a variety of cancers in Phase I and II clinical trials and is similar to its predecessors such as the ansamycin class of molecules. To our knowledge, nanoformulations for luminespib remain unexplored for their anticancer potential. In the present study, we developed aqueous dispensable BSA NPs for controlled delivery of luminespib. The luminespib-loaded BSA NPs were characterized by SEM, TEM, FTIR, XPS, UV-visible spectroscopy and fluorescence spectroscopy. The results suggest that luminespib interacts by non-covalent reversible interactions with BSA to form drug-loaded BSA NPs (DNPs). Our in vitro evaluations suggest that DNP-based aqueous nanoformulations can be used in both pancreatic (MIA PaCa-2) and breast (MCF-7) cancer therapy.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (S1101017)
- Inoue Enryo Research Grant (NA)
This publication has 45 references indexed in Scilit:
- Unraveling the binding interaction and kinetics of a prospective anti-HIV drug with a model transport protein: results and challengesPhysical Chemistry Chemical Physics, 2012
- Hsp90 inhibitors and drug resistance in cancer: The potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugsBiochemical Pharmacology, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- Exploring the binding mechanism of dihydropyrimidinones to human serum albumin: Spectroscopic and molecular modeling techniquesColloids and Surfaces B: Biointerfaces, 2011
- Management Options in Triple-Negative Breast CancerBreast Cancer: Basic and Clinical Research, 2011
- Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitroActa Pharmacologica Sinica, 2009
- New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potentialDrug Resistance Updates, 2009
- NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsBreast Cancer Research, 2008
- Structure-based discovery of a new class of Hsp90 inhibitorsBioorganic & Medicinal Chemistry Letters, 2005
- Heat shock proteins as emerging therapeutic targetsBritish Journal of Pharmacology, 2005